Skip to main content
. 2022 Aug 23;82(12):1287–1302. doi: 10.1007/s40265-022-01756-6

Table 1.

Study characteristics

References Study Year Sample size Antithrombotic regimena Populationb Average follow-up (months) Age (mean) Male (%) HT (%) HL (%) CSM (%) HSM (%) CAD (%) CVD (%) DM (%)
[36] Becquemin 1997 243 P vs TP2 PVI 24 67 77 51 25 22 23 24
[15] BOA 2000 2690 A vs VKA2 PVI 21 69 64
[37] CABBAGE 2017 50 A vs A+CI PVI 3 73 74 88 50 14 40 54 26 74
[13] CAPRIE 1996 6452 A vs C PAD 23 64 72 51 45 38 90 54 14 21
[38] CASPAR 2010 851 A vs A+C PVI 12 66 76 70 50 38 35 37
[39] CHARISMA 2009 3096 A vs A+C PAD 26 60 70 72 70 32 85 25 16 36
[40] CLIPS 2007 366 A vs P PAD 21 66 77 62 26 80 76
[16] + [41] COMPASS 2018 7470 A vs A+R1 vs R2 PAD 21 68 72 79 28 75 65 7 45
[42] COOPER 2012 431 C vs TP1 PAD 3 71 88 74 56 25 88 13 18 33
[33] CREDO 2006 272 A vs A+C CAD 12 67 66 76 74 30 100 32
[44] ePAD 2018 203 A+C vs A+E PVI 2.7 67 29 83 35 86 40
[35] EUCLID 2017 13,885 C vs TG2 PAD 30 66 72 78 76 31 78 29 12 39
[45] Gresele 2000 159 A vs A+CC PAD 6 66 86 45 64 84 25
[46] Johnson 2002 831 A vs A+VKA1 PVI 38 64 88 25 17 36
[47] Li 2013 50 C vs C+VKA1 PVI 12 74 66 70 24 51 59 20 42
[48] MIRROR 2011 80 A vs A+C PVI 6 70 53 78 63 40 33 19 38
[49] Monaco 2012 318 A+C vs C+VKA1 PVI 77 67 70 81 24 61 48
[50] PEGASUS TIMI 54 2016 1143 A vs A+TG1 vs A+TG2 CAD 36 66 78 85 81 30 100 3 42
[51] PLATO 2015 1144 A+C vs A+TG2 CAD 9 66 75 79 66 38 74 100 15 38
[52] RIVAL-PAD 2020 20 A+C vs A+R1 PVI 3 67 60 0 0
[53] Soga 2009 80 A+TP1 vs A+TP1+CI PVI 24 71 83 49 33 39 54 9 [36
[54] STOP-IC 2013 200 A vs A+CI PVI 12 73 59 81 47 461 39 56
[17] VOYAGER-PAD 2020 6564 A vs A+R1 PVI 28 67 74 81 60 35 32 40
[55] WAVE 2007 2161 A vs A+ VKA1 PAD 35 64 74 58 29 39 47 16 27

CAD coronary artery disease, CSM current smoker, CVD cerebrovascular disease, DM diabetes mellitus, HL hyperlipidaemia, HSM history of smoking, HT hypertension, INR international normalized ratio

aAntithrombotic regimen: A acetylsalicylic acid 75–325 mg daily, C clopidogrel 75 mg once daily, CC cloricromene 100 mg twice daily, CI cilostazol 200 mg once daily, E edoxaban 60 mg once daily, P placebo only, R1 rivaroxaban 2.5 mg twice daily, R2 rivaroxaban 5 mg twice daily, TG1 ticagrelor 60 mg twice daily, TG2 ticagrelor 90 mg twice daily, TP1 ticlopidine 200 mg twice daily, TP2 ticlopidine 250 mg twice daily, VKA1 vitamin K antagonist with target INR between 1.4 and 3, VKA2 vitamin K antagonist with target INR between 3 and 4.5

bPopulation: CAD studies on patients with coronary artery disease who coincide with peripheral arterial disease, PAD studies on patients who are solely selected for peripheral arterial disease, PVI studies on patients who underwent a peripheral vascular intervention for peripheral arterial disease